Briacell Therap (NASDAQ:BCTX) Short Interest Up 40.2% in March

Briacell Therap (NASDAQ:BCTX) was the recipient of a large growth in short interest during the month of March. As of March 13th, there was short interest totaling 145,756 shares, a growth of 40.2% from the February 26th total of 103,944 shares. Currently, 2.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 273,289 shares, the short-interest ratio is presently 0.5 days.

Briacell Therap Stock Performance

BCTX stock opened at $3.75 on Monday. The firm has a market cap of $27.19 million, a P/E ratio of -0.16 and a beta of 1.46. The firm’s fifty day moving average is $4.17 and its 200 day moving average is $7.87. Briacell Therap has a 52 week low of $3.60 and a 52 week high of $98.20.

Briacell Therap (NASDAQ:BCTX) last posted its quarterly earnings results on Tuesday, March 10th. The company reported ($2.58) earnings per share for the quarter. As a group, analysts forecast that Briacell Therap will post -2.45 EPS for the current year.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Briacell Therap in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $320.00.

Institutional Investors Weigh In On Briacell Therap

An institutional investor recently bought a new position in Briacell Therap stock. Citadel Advisors LLC purchased a new position in shares of Briacell Therap (NASDAQ:BCTX) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm purchased 11,055 shares of the company’s stock, valued at approximately $122,000. Citadel Advisors LLC owned about 1.63% of Briacell Therap at the end of the most recent reporting period. 15.42% of the stock is currently owned by institutional investors.

Briacell Therap Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.